CompePharma View: Guide the engine, not the average, and show your range

The raise is the headline. The shape of the range is the story.

Third-quarter reports from PTC Therapeutics, Acadia, Ironwood, Corcept, ANI and Krystal tell a similar story of growth. The more useful signal is what each company did with its full-year guidance. A beat is history. A range is a commitment, and this season it shows who is willing to be specific.

PTC raised total 2026 revenue guidance to $1.29-$1.32 billion and product revenue to $960-$990 million, on Sephience revenue of $182 million in the quarter. Acadia raised DAYBUE net sales guidance to $505-$520 million while narrowing its NUPLAZID and total revenue ranges. Ironwood lifted LINZESS U.S. net sales guidance to $1.20-$1.25 billion, alongside total revenue of $485-$510 million and adjusted EBITDA above $350 million. ANI narrowed total revenue to $1,085-$1,125 million, revised Cortrophin Gel to $480-$500 million, and raised adjusted EBITDA and adjusted EPS. Corcept, with Q3 revenue up 64% to $340.5 million, reiterated $1.1-$1.2 billion.

Our position: specificity is the new credibility

The pattern worth noting is granularity. Acadia separated the product it was raising from the ones it was only narrowing. Ironwood put a number on the franchise driving its result, and said year-to-date LINZESS U.S. sales of $880 million already exceed full-year 2025. ANI broke out Cortrophin Gel while moving its profit guidance. Management in each case showed investors where the confidence sits rather than offering a blended average.

Range width carries information too. Acadia's DAYBUE range spans $15 million, ANI's Cortrophin range $20 million, PTC's total revenue range $30 million. Corcept's reiterated range spans $100 million. A wide range may reflect real uncertainty or simple caution, and the material does not say which. But for a company with a 64% growth rate and a quarter that large, readers will ask the question, and management should expect to answer it.

Our view is that guidance now works as a disclosure in its own right. Companies that raise at the product level, narrow where visibility has improved and explain what is left in the range will earn more trust than those that deliver a strong quarter and repeat last quarter's guidance.

The strongest counter-argument

The best objection is that guidance in a strong season is cheap. When launches and mature products are all running ahead of plan, raising a number is easy, and reiterating one is a defensible act of prudence rather than a signal. Corcept's unchanged range could simply reflect a company that sets its guidance once and revisits it rarely. Wide ranges also protect management from the volatility that specific, tight numbers invite, and a company that narrows early can be punished if one quarter disappoints.

That is fair, and we would not read too much into any single range. But the argument cuts the other way as well. If guidance is merely a conservative formality, it should be tight where visibility is high and explicitly wide where it is not, with the reasons stated. What we cannot accept is unexplained ambiguity from a company posting 64% growth and a net income of $126.8 million against $19.7 million a year earlier. Prudence is a reason, and it should be given as one.

What it means for the industry

Rare-disease and specialty names are growing quickly enough that the outside world will treat their guidance as a forecast rather than a floor. PTC says it is on track for cash flow breakeven this year. Krystal, which reported $127.3 million in VYJUVEK revenue and a $400 million buyback, is signalling that growth is funding both pipeline and returns. Those claims rest on forward numbers, and the forward numbers need to be credible and well supported.